{"id":"W4396827653","doi":"10.1016/s1470-2045(24)00178-5","title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Foundation Medicine; Sanofi Genzyme; Chugai Pharmaceutical; University of Texas MD Anderson Cancer Center; EMD Serono; Silverback Therapeutics; Bavarian Nordic; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Seagen; G1 Therapeutics; Genentech; UroGen Pharma; Pfizer; Incyte; Ipsen; Mirati Therapeutics; Amgen; Bladder Cancer Canada; Sanofi; Exelixis; Regeneron Pharmaceuticals; Boston Scientific Corporation; AstraZeneca; Invitae; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Carcinoma in situ; Cystectomy; Bladder cancer; Cohort; Internal medicine; Oncology; Carcinoma; Cancer; Urology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003640559,0.0003320103,0.0009389044,0.0001988966,0.0001112348,0.00004572853,0.0001666758,0.0002044712,0.0001057161],"category_scores_gemma":[0.0001900221,0.0002260122,0.0001197583,0.0002830061,0.0001370046,0.00007271297,0.000056154,0.0003607281,0.0000248222],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006129021,"about_ca_system_score_gemma":0.0008720526,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002136223,"about_ca_topic_score_gemma":0.005452744,"domain_scores_codex":[0.997936,0.0002695615,0.0003811409,0.0006054268,0.0001886279,0.0006192727],"domain_scores_gemma":[0.9981565,0.001038405,0.0001078744,0.0003988515,0.0001061776,0.0001921426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6197512,0.002945949,0.003329514,0.0003407281,0.001378385,0.0008647371,0.02325251,0.00008539399,0.03175519,0.0002842503,0.009063076,0.3069491],"study_design_scores_gemma":[0.795262,0.06180083,0.02781671,0.0006539145,0.002770047,0.0001945314,0.001904056,0.001307622,0.02707491,0.00210021,0.07815681,0.0009582977],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805564,0.002341398,0.0003200414,0.01027942,0.001116463,0.004273192,0.0003188784,0.00008207218,0.0007121476],"genre_scores_gemma":[0.9901028,0.001007734,0.000827367,0.003839063,0.00217295,0.001446241,0.00002801742,0.00007567831,0.0005001773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3059908,"threshold_uncertainty_score":0.9216509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05105573192091713,"score_gpt":0.3836772905862923,"score_spread":0.3326215586653752,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}